Quantcast
Home > Quotes > ARPO

Aerpio Pharmaceuticals, Inc. Common Stock (ARPO) Quote & Summary Data

ARPO 
$1.97
*  
0.07
3.68%
Get ARPO Alerts
*Delayed - data as of Dec. 18, 2018  -  Find a broker to begin trading ARPO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ARPO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
10
Today's High / Low
$ 2.06 / $ 1.90
Share Volume
178,485
50 Day Avg. Daily Volume
62,387
Previous Close
$ 1.90
52 Week High / Low
$ 4.35 / $ 1.75
Market Cap
79,958,368
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.28

Intraday Chart

Shares Traded

Share Volume:
178,485
50 Day Avg. Daily Volume:
62,387

Trading Range

The current last sale of $1.97 is 12.57% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.06 $ 4.35
 Low: $ 1.90 $ 1.75

Company Description (as filed with the SEC)

Aerpio is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Our lead product candidate, AKB-9778, a small molecule activator of the Tie2 pathway, is being developed for the treatment of diabetic retinopathy, or DR, a disease characterized by progressive compromise of blood vessels in the back of the eye. The Tie2 receptor is expressed almost exclusively in endothelial cells (cells that make up blood vessels) and is essential for regulating vascular stability and preventing blood vessel compromise associated with diabetes. We have completed a Phase 2a trial of AKB-9778 in 144 patients with diabetic eye disease. Based on the results from this trial, we believe AKB-9778 has the potential to stop, slow down or reverse the damage to blood vessels caused by diabetes.  ... More ...  


Risk Grade

Where does ARPO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.94
Open Date:
Dec. 18, 2018
Close Price:
$ 1.97
Close Date:
Dec. 18, 2018

Consensus Recommendation

Analyst Info